Harley-Davidson in Summer SLOWDOWN and 3 HOT Stock Analyses to Note
Gilead Sciences Inc. (NASDAQ:GILD): After the Federal Drug Administration approved Stribild for the treatment of HIV infection, Needham raised their price target for Gilead. Needham noted that the drug’s wholesale acquisition cost is $2,342 per month, a premium comparable to Atripla and Complera. The firm reiterates a Buy rating on shares of Gilead.
Don’t Miss: What Has Tiffany’s and Best Buy SMILING?
Take-Two Interactive Software Inc. (NASDAQ:TTWO): After conducting checks, Sterne Agee believes that Take-Two’s “Borderlands 2” game could exceed expectations. The firm maintains a $17 target and Buy rating on their shares.
Immunogen Inc. (NASDAQ:IMGN): After Immunogen (NASDAQ:IMGN) and Roche (RHHBY) reported significantly improved overall survival data from the T-DM1 in 2nd line metastatic breast cancer, Roth Capital believes that as soon as the drug is approved by the Federal Drug Administration in 2013, there will be a more rapid sales growth. The firm expects the drug to obtain FDA approval in 2013 and it maintains a $19 target and Buy rating on Immunogen.
Harley-Davidson, Inc. (NYSE:HOG): UBS believes that the U.S. retail dealer sales are down into mid-single digits to approximately (2%), below 2012 levels. The firm does not view the weakness as a surprise given the difficult comps and the pushout of enterprise resource planning implementation. Shares are Neutral rated with a $45 price target.
Don’t Miss: Apple Is On A RAMPAGE.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.